US6132726A - Process for removing impurities from natural product extracts - Google Patents
Process for removing impurities from natural product extracts Download PDFInfo
- Publication number
- US6132726A US6132726A US09/176,348 US17634898A US6132726A US 6132726 A US6132726 A US 6132726A US 17634898 A US17634898 A US 17634898A US 6132726 A US6132726 A US 6132726A
- Authority
- US
- United States
- Prior art keywords
- impurities
- column
- eluent
- columns
- crude extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 59
- 239000000284 extract Substances 0.000 title claims abstract description 22
- 239000012535 impurity Substances 0.000 title claims description 39
- 230000008569 process Effects 0.000 title abstract description 23
- 229930014626 natural product Natural products 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 239000000287 crude extract Substances 0.000 claims abstract description 45
- 239000000463 material Substances 0.000 claims abstract description 45
- 230000002745 absorbent Effects 0.000 claims abstract description 27
- 239000002250 absorbent Substances 0.000 claims abstract description 27
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 5
- 229930182494 ginsenoside Natural products 0.000 claims description 50
- 241000196324 Embryophyta Species 0.000 claims description 32
- 240000004371 Panax ginseng Species 0.000 claims description 30
- 239000000575 pesticide Substances 0.000 claims description 30
- 235000008434 ginseng Nutrition 0.000 claims description 29
- LKPLKUMXSAEKID-UHFFFAOYSA-N pentachloronitrobenzene Chemical compound [O-][N+](=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl LKPLKUMXSAEKID-UHFFFAOYSA-N 0.000 claims description 28
- 239000003480 eluent Substances 0.000 claims description 22
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 claims description 18
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 14
- 235000002789 Panax ginseng Nutrition 0.000 claims description 14
- 239000011159 matrix material Substances 0.000 claims description 14
- CKAPSXZOOQJIBF-UHFFFAOYSA-N hexachlorobenzene Chemical compound ClC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl CKAPSXZOOQJIBF-UHFFFAOYSA-N 0.000 claims description 12
- 239000000417 fungicide Substances 0.000 claims description 10
- LGZZJTIUEJNNKV-UHFFFAOYSA-N 1,2,3,4,5-pentachloro-6-methylsulfanylbenzene Chemical compound CSC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl LGZZJTIUEJNNKV-UHFFFAOYSA-N 0.000 claims description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 239000001569 carbon dioxide Substances 0.000 claims description 6
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 claims description 6
- 229960002809 lindane Drugs 0.000 claims description 6
- CEOCDNVZRAIOQZ-UHFFFAOYSA-N pentachlorobenzene Chemical compound ClC1=CC(Cl)=C(Cl)C(Cl)=C1Cl CEOCDNVZRAIOQZ-UHFFFAOYSA-N 0.000 claims description 6
- XQTLDIFVVHJORV-UHFFFAOYSA-N tecnazene Chemical compound [O-][N+](=O)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl XQTLDIFVVHJORV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004009 herbicide Substances 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 241000168720 Panax japonicus Species 0.000 claims description 4
- 235000003174 Panax japonicus Nutrition 0.000 claims description 4
- 241000180649 Panax notoginseng Species 0.000 claims description 4
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 4
- 240000005373 Panax quinquefolius Species 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229920006122 polyamide resin Polymers 0.000 claims description 3
- 229920005990 polystyrene resin Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000012454 non-polar solvent Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- QHIWVLPBUQWDMQ-UHFFFAOYSA-N butyl prop-2-enoate;methyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C(C)=C.CCCCOC(=O)C=C QHIWVLPBUQWDMQ-UHFFFAOYSA-N 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 8
- 239000012467 final product Substances 0.000 abstract description 3
- 230000033001 locomotion Effects 0.000 abstract description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 15
- 238000000605 extraction Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- KHCZSJXTDDHLGJ-UHFFFAOYSA-N 2,3,4,5,6-pentachloroaniline Chemical compound NC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl KHCZSJXTDDHLGJ-UHFFFAOYSA-N 0.000 description 7
- 239000000356 contaminant Substances 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000012632 extractable Substances 0.000 description 5
- 231100000628 reference dose Toxicity 0.000 description 5
- 239000002028 Biomass Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000005445 natural material Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 231100000693 bioaccumulation Toxicity 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000000855 fungicidal effect Effects 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010960 commercial process Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DQNOIKMHTBFYTD-UHFFFAOYSA-N n,n,2,3-tetrachloroaniline Chemical compound ClN(Cl)C1=CC=CC(Cl)=C1Cl DQNOIKMHTBFYTD-UHFFFAOYSA-N 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229940076742 senna leaves Drugs 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- -1 such as Polymers 0.000 description 2
- 230000003390 teratogenic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical class C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- YTDHEFNWWHSXSU-UHFFFAOYSA-N 2,3,5,6-tetrachloroaniline Chemical compound NC1=C(Cl)C(Cl)=CC(Cl)=C1Cl YTDHEFNWWHSXSU-UHFFFAOYSA-N 0.000 description 1
- IPQVTOJGNYVQEO-UHFFFAOYSA-N 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical class OC1C(O)C(O)C(CO)OC1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2C1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(OC3C(C(O)C(O)C(CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 231100000264 OECD 451 Carcinogenicity Study Toxicity 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 240000009305 Pometia pinnata Species 0.000 description 1
- 235000017284 Pometia pinnata Nutrition 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000000768 catecholaminergic effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000011437 continuous method Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000008235 industrial water Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000447 pesticide residue Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical class C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229930186851 sennoside Natural products 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Definitions
- the present invention relates to a continuous process for separating organic compounds contained in an extract based on polarity. More particularly, the present invention relates to a commercial process whereby a target compound of interest may be purified by removing undesirable compounds that are more polar or less polar than the target compound.
- the main root is a fleshy tap root, branched into smaller rootlets. At the age of 4 to 6 years, when most of the cultivated plants are harvested, their roots usually are about 2 to 3 centimeters in diameter and about 10 to 20 centimeters in length.
- the ginsenosides a family of saponins, are believed to be the most important.
- the ginsenosides are made up of two groups, Rg and Rb, each containing several related compounds. Studies have indicated that most of the physiologic effects of ginseng can be related to the ginsenosides.
- the Rg group consists of derivatives of protopanaxatriol and includes Rg 1 , Re, Rf, Rg 2 , and several other related compounds. This group is believed to possess the stimulatory effect on the central nervous system.
- the Rb group consists of derivatives of protopanaxadiol and includes Rb 1 , Rb 2 , Rc, Rd, and several other related compounds. This group is believed to possess the depressant effect on the central nervous system.
- ginseng One of the best studied and documented activities of ginseng is its ability to act as a stimulant and anti-fatigue agent. Further studies have also indicated that Panax ginseng could increase locomotion activity and modify feline EEG recording. Panax ginseng's adaptogenic effects are believed to be due to the action of ginsenosides on the adrenal cortex and on the brain. In 1985, Saito found, from studies with mice and organ cultures, that ginsenoside Rb 1 plays an important role in the catecholamine synthesis of catecholaminergic neurons of the brain, in the ganglion and in the chromaffin cells of the adrenal cortex, as well as in the formation of nerve fibers and in the function of the sympathetic nerve endings.
- Rg 1 The foundation of these various nerve fibers are important in maintaining glucocorticoid secretion, which regulates the bodies ability to deal with stress.
- Rg 1 is believed to play an important role in the memory and in sexual behavior.
- CTH adrenocorticotropic hormone
- Panax ginseng may also have the ability to enhance the body's natural immune system by increasing the rate of phagocytosis.
- phagocytes Several types of white blood cells are generically known as "phagocytes.” Phagocytes attack, engulf and release powerful enzymes that destroy invaders in the blood stream, including microorganisms and pathogens through a process referred to as phagocytosis.
- Panax ginseng plants are treated during their growing season with numerous herbicides and fungicides which ultimately always lead, regardless of their form, to residues in the ginseng product, even though sometimes in minute amounts. These residues are understandably undesireable in every case, as is underlined by the intensive public debate surrounding their use.
- Raw materials used in the production of medicinal products are especially subject to critical evaluation since medicinal products have proven, on account of the demand for purity, to be a very sensitive consumed substance. Consequently, it would be considered advantageous, if it were possible, to produce medicinal products extracted from natural products, having a very low residue content.
- PCNB chlorinated benzene derivative pentachloronitrobenzene
- PCNB is used as a herbicide and fungicide for seed and soil treatment, and as a slime inhibitor in industrial waters.
- PCNB has been found in drinking water, well water, crop land and nursery soils, spinach leaves, cheese, fruits, ground grains, leaf and stem vegetables, nuts, oil seed by-products and more recently in ginseng products. The most probable route of human exposure to PCNB is through the ingestion of contaminated food.
- PCNB pentachloroaniline
- PCTA pentachlorothioanisole
- HBC hexachlorobenzene
- Toxicity of PCNB is observed in animals and humans only at doses in the multiple mg/kg body weight range.
- the acute lethal dose for humans is estimated to be 500 mg/kg or greater.
- the EPA-established Reference Dose (RfD) for quintozene is 0.003 mg/kg/day. EPA estimates that consumption of this dose or less over a lifetime would not likely result in the occurrence of chronic, noncancer effects. This RfD is based on liver toxicity in dogs, including increased liver weight and effects on liver enzymes. EPA has medium confidence in the RfD because the principal study on which the RfD is based appears to be of fair quality, and because of the lack of a complete database on chronic toxicity.
- the EPA allowable daily intake (ADI) is 0.007 mg/kg/day, and the allowable daily intake from the UN CODEX Alimentarius is 0.01 mg/kg/day.
- ADI allowable daily intake
- the health risk posed by any chemical, even a carcinogenic compound depends on the dose at the target site of action as well as its potency in producing an adverse health effect.
- PCNB has been observed to bioaccumulate in tissues only at trace or very low concentrations. Two of its metabolites, PCA and PCTA, likewise do not significantly bioaccumulate in tissues. HCB, on the other hand, has significant bioaccumulation.
- PCNB quintozene
- HCB has significant bioaccumulation.
- PCNB quintozene
- quintozene which is regarded as being the main contaminant of ginseng roots and thus a leading substance for undesired, lipophilic, chlorinated pesticides, is only reduced to about 30% so that the extracted ginseng roots do not even approach the region of commercial usefulness when the pesticide content exceeds the permitted values.
- Another object of the present invention is to separate, from a mixture of compounds, those compounds that are more polar or less polar than the target compound.
- a further object of the invention is to separate ginsenosides from undesired compounds that are more polar or less polar.
- the method of this invention comprises an extract containing a mixture of compounds having varying polarities that is subsequently fractionated using a series of columns containing an absorbent material.
- the vertical axis represents the percentage of micrograms of analyte in starting material and the horizontal axis represents the number of column volumes of eluent passed over the column.
- FIG. 1 is a schematic representation of the series of columns used to carry out the method of the present invention.
- FIG. 2 graphically represents the quantity of ginsenosides per column volume (CV) eluting from columns 1 through 4.
- FIG. 3 graphically represents the quantity of pesticides per column volume (CV) eluting from column 1.
- the present invention relates to a process for the removal of undesireable compounds or residues from an extract which are more polar or less polar than the desired target compound.
- pesticide and fungicide contaminants or residue contaminants are the undesireable compounds that are being removed from an extract of Panax ginseng having ginsenosides as the target compounds.
- a Panax ginseng extract is named in this connection only by way of example, since the problem of removing undesireable residues occurs in numerous natural substances, whether the starting materials are wild or cultivated.
- the preferred embodiment of the present invention is a three step process and is described in detail below.
- the first step includes contacting a plant material that contains the desired target compound(s) with a solvent, thus producing a crude extract containing a mixture of compounds that includes, in addition to the undesireable residues, the desired target compound(s).
- the second step involves passing the crude extract through a series of columns containing an absorbent that retards the movement of the undesireable compounds, while allowing the desired compounds to pass.
- the series of columns is critical to the continuous method of the present invention as will be discussed in further detail below.
- the third and final step involves drying the eluant product to achieve a final product.
- This invention includes a process for the extraction of ginsenosides and the removal of undesireable compounds, such as pesticides and fungicides from plant materials or biomasses that contain ginsenosides.
- ginsenosides include Panax ginseng, Panax quinquefolium, Panax japonicum, and Panax notoginseng.
- this list is exemplary of the plant materials that contain ginsenosides, and is not meant to limit the scope of plant materials which may be utilized by the present invention. It has further been ascertained that the separation of undesireable materials by the method of the invention is also successful with a wide variety of starting materials other than Panax ginseng.
- undesireable residues that are less polar or more polar than the desired target compound can be removed in accordance with the present invention during the recovery of the following categories of natural substances:
- vegetable oils for example, from oil-bearing seeds, seeds and nuts;
- aromatic and odorous substances for example, from fruits, vegetables, herbs and tobacco;
- spice extracts for example, from spice plants such as, vanilla, garlic, pepper and cinnamon.
- the first step in the process of the present invention extraction of the target compounds in this particular instance the target compounds are ginsenosides compounds, is preferably accomplished by mixing or contacting a solvent, such as an alcohol, and preferably ethanol or methanol with a plant material containing ginsenosides. Depending on the type of plant material used, it may be necessary to grind it into a range of 0.1-10 mm. The degree of comminutation of the plant material should provide sufficient particulate surface area for the solvent to contact, but depends on the type of plant material used. The skilled person in this art will recognize that a variety of extraction methods are available in the literature, such as, percolation, vat extraction, counter-current extraction, etc.
- the particular method of extraction employed is not essential to the process of the present invention.
- the temperature of extraction is between room temperature or about 22° C. to about 70° C., with 50-60° C. being preferred; however, the temperature is not essential to this invention.
- the amount of plant material to solvent mixture used in the extraction process varies between 1:1 to 1:10 on a gram:milliliter basis, with 1:1 to 1:3 being preferred; however, this mixture is not essential to the invention.
- the ginsenosides and some of the extraneous materials that are contained in the comminuted plant material are soluble in the solvent used.
- the solvent, the ginsenosides and some of the extraneous materials including the undesireable residues from fungicides or pesticides form the crude extract.
- the crude alcohol extract may be diluted with distilled water to a final volume of approximately 40-75% alcohol in water and preferably 55-65% alcohol in water.
- the resulting solution is then filtered to remove insoluble materials. It has been found that the ratio of solvent to water has a significant effect on the quantity of pesticides that are extracted from the comminuted plant material. That is to say, extraction using 75% and greater alcohol in water, results in a greater extraction of pesticides and ginsenosides, while a 55-65% alcohol in water solvent results in a reduced amount of pesticides and ginsenosides being extracted.
- the second step the removal of the undesireable compounds which may be less polar or more polar than the ginsenosides begins.
- the crude extract contains not only the desired ginsenosides, and the undesireable compounds, but also extraneous plant materials that are soluble in the solvent of the crude extract. It is desirable to remove the undesireable compounds from the crude extract, resulting in the recovery of the ginsenosides and extraneous materials in as close as possible to their natural profile.
- the crude extract which may be diluted with water is placed in contact with an absorbent material or matrix.
- the matrix that is chosen is dependent upon the polarity of the compounds to be separated. Consequently, if the undesireable compounds are more polar than the target compound, a normal phase matrix such as silica gel or fluorasil is used. However, if the undesireable compounds are less polar than the target compound, a reversed phase matrix is used. It should be noted that the process of the present invention is operational only as long as the polarity of the compounds to be separated do not overlap.
- the undesireable compounds are less polar than the ginsenosides; consequently, the preferred absorbent is a polystyrene resin, such as, XAD-16TM, manufactured by Rohm & Haas, or HP 2055 manufactured by Mitsubishi Kasai.
- Other reversed phase matrixes that can be used but are not limited to, are acrylic resins, such as, ToSoHaas CG-161TM, polyamide resins, such as, Polyamide-Nylon 6, or C-18.
- the crude extract is placed in contact with a matrix that is capable of absorbing the undesireable compounds of a particular polarity. Consequently, those compounds whose polarity do not allow for absorption, are not retained.
- the container that holds the matrix could be a vat type container with or without a stirrer, a single column or multiple columns; however, the preferred embodiment of the present invention contemplates using a series of columns.
- FIG. 1 is illustrative of the series of columns, each of which is properly packed with an absorbent that is used to remove the undesireable compounds present in the crude extract.
- the columns are prepared in accordance with the resin manufacturer's recommended procedures.
- Crude extract containing the ginsenosides and some of the extraneous materials, including the undesireable residues from fungicides or pesticides, is continuously loaded onto the first column 100.
- the crude extract filters down over the absorbent (not shown) until it exits column 100 where it is then directed through columns 110, 120 and 130 by way of a series of pipes and valves.
- Table 1 indicates that no detectable levels of undesireable compounds elute from column 100 until approximately eight column volumes of extract have flowed over the absorbent in column 100. This is a fact that the method of the present invention exploits.
- the ginsenosides shown in FIG. 2 are eluting from column 100 after only two column volumes of crude extract has flowed over the absorbent while the undesireable compounds (shown in FIG. 3) begin to elute from column 100 after four column volumes. Consequently, the entire crude extract eluting between zero and four column volumes, indicated as area 50, is void of the undesireable compounds, and this entire volume is the desired eluant product.
- the crude extract less the undesireable compounds eluting from column 110 is directed into a third column 120.
- the ginsenosides are eluting from column 120 by six column volumes.
- up to twenty-eight column volumes elute from column 120 before any undesireable compounds are detected.
- the first column 100 is spent or exhausted after approximately twenty-four column volumes has passed over the column. Consequently, valves 98 and 102 can be closed, allowing for the removal and reconstitution of column 100.
- the crude extract formed during the first step is redirected to enter column 110 through pipe 108.
- valves 106 and 112 are closed, allowing for the cleaning and reconstitution of column 110.
- This procedure continues down the line until extract eluting from column 140 is directed to freshly constituted column 100.
- This cyclical pattern is extremely advantageous in a commercial setting because it alleviates the need to take the entire process off-line while one column is being reconstituted and it allows the matrix to be completely exhausted.
- the preferred third and final step in the process is the drying of the final product.
- An appropriate amount of excipient such as but not limited to, maltodextrin, dicalcium phospate (DCP) or tricalcium phosphate (TCP), is added to the product from step two, thus bringing the ginsenosides to the 7% level and the product is dried on to this excipient, using a rotary evaporator, spray drier, lyophilizer or any other appropriate drying device.
- the ground biomass can be subjected to an initial wash with an appropriate solvent such as hexane, heptane, MTBE, acetone, or an alcohol such as ethanol to remove the desired pesticides while retaining the desired extractables.
- an appropriate solvent such as hexane, heptane, MTBE, acetone, or an alcohol such as ethanol to remove the desired pesticides while retaining the desired extractables.
- This extraction may need to be done at some temperature other than at room temperature.
- the biomass was extracted as usual to recover the desired extractables. This step can be repeated as often as needed.
- Ginseng biomass with quintozene at 10.6 ppm was ground in a Wiley mill and then extracted three times with hexane which lowered the pesticide level in the biomass to 0.7 ppm.
- dried ginseng extract produced after the first step of the preferred embodiment containing 17.4 ppm quintozene was supercritically extracted with CO 2 which lowered the pesticide to 12.0 ppm in one experiment.
- an alcohol/water extract of an herbal or an alcohol/water solution containing the herbal extractables can be liquid/liquid extracted with a non-polar solvent such as but not limited to hexane, heptane, MTBE, or ether. This extraction can be repeated as often as needed.
- An ethanol/water solution of ginseng extractables containing 18.3 ppm quintozene was extracted three times with heptane reducing the fungicide to 1.55 ppm in one experiment.
- an alcohol/water extract of an herbal or an alcohol/water solution containing the herbal extractables can be contacted with an absorbent form of carbon. After the carbon is removed, it should be thoroughly washed to optimize Panax ginseng recovery. This step can be repeated as often as needed.
- This approach using CarbographTM manufactured by Phenomenex, reduced the quintozene in ginseng from 18.3 ppm to 0.92 ppm in one experiment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Extraction Or Liquid Replacement (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
______________________________________
Rg Group
##STR1##
Ginsenoside
R.sub.1 R.sub.2
______________________________________
Rg.sub.1
D-Glucose D-Glucose
Re L-Rhamnose-(α-1-2)-D-Glucose
D-Glucose
Rf D-Glucose-(β-1-2)-D-Glucose
H
Rg.sub.2
L-Rhamnose-(α-1-2)-D-Glucose
H
______________________________________
__________________________________________________________________________
Rb Group
##STR2##
Ginsenoside
R.sub.1 R.sub.2
__________________________________________________________________________
Rb.sub.1
D-Glucose-(β-1-2)-D-Glucose
D-Glucose-(β-1-6)-D-Glucose
Rb.sub.2
D-Glucose-(β-1-2)-D-Glucose
L-arabinopyranoside-(α-1-6)-D-Glucose
Rc D-Glucose-(β-1-2)-D-Glucose
L-arabinofuranoside-(α-1-6)-D-Glucose
Rd D-Glucose-(β-1-2)-D-Glucose
D-Glucose
__________________________________________________________________________
TABLE 1
__________________________________________________________________________
Original
Concentration
1st Column 100
Undesireable
in the Column Volumes
Compounds Crude Extract
4 8 12 16 20 24 28
__________________________________________________________________________
Pentachlorobenzene
0.15 nd nd nd nd nd 0.00
0.01
2,3,5,6- 0.2 nd nd nd 0.01
0.03
0.06
0.10
Tetrachloronitrobenzene
2,3,5,6- 0.08 nd nd 0.01
0.04
0.06
0.08
0.08
Tetrachloroaniline
BHC alpha isomer
0.48 nd nd 0.09
0.36
0.42
0.57
0.54
Hexachlorobenzene
0.25 nd nd nd nd nd nd nd
BHC beta isomer
0.25 nd nd 0.16
0.27
0.21
0.25
0.24
Lindane 0.38 nd nd 0.16
0.38
0.37
0.47
0.42
Pentachloronitrobenzene
1.68 nd nd nd nd 0.02
0.04
0.11
BHC delta isomer
0.88 nd 0.12
0.60
1.03
0.82
0.96
0.88
Pentachloroaniline
1.35 nd 0.01
0.16
0.79
1.03
1.44
1.41
Pentachlorothioanisole
0.1 5 nd nd nd nd nd nd nd
Total 5.83 0.00
0.13
1.19
2.88
2.96
3.87
3.79
__________________________________________________________________________
All Units are expressed in μg/mL.
TABLE 2
__________________________________________________________________________
Original
Concentration
2nd Column 110
Undesireable
in the Column Volumes
Compounds Crude Extract
10 14 18 22 26 28
__________________________________________________________________________
Pentachlorobenzene
0.15 nd nd nd nd nd nd
2,3,5,6- 0.2 nd nd nd nd nd nd
Tetrachloronitrobenzene
2,3,5,6- 0.08 nd nd nd 0.004
0.01
0.02
Tetrachloroaniline
BHC alpha isomer
0.48 nd nd nd nd 0.06
0.15
Hexachlorobenzene
0.25 nd nd nd nd nd nd
BHC beta isomer
0.25 nd nd nd 0.08
0.20
0.30
Lindane 0.38 nd nd nd nd 0.16
0.30
Pentachloronitrobenzene
1.68 nd nd nd nd nd nd
BHC delta isomer
0.88 nd 0.01
0.07
0.38
0.79
1.20
Pentachloroaniline
1.35 nd 0.004
0.004
0.01
0.08
0.25
Pentachlorothioanisole
0.15 nd nd nd nd nd nd
Total 5.83 0.00
0.02
0.08
0.48
1.30
2.22
__________________________________________________________________________
All Units are expressed in μg/mL.
TABLE 3
______________________________________
Original 3rd Column
Product
Concentration
120 Pool
Undesireable in the Column Volumes
Compounds Crude Extract
10 28
______________________________________
Pentachlorobenzene
0.15 nd nd
2,3,5,6-Tetrachloronitrobenzene
0.2 nd nd
2,3,5,6-Tetrachloroaniline
0.08 nd nd
BHC alpha isomer
0.48 nd nd
Hexachlorobenzene
0.25 nd nd
BHC beta isomer 0.25 nd nd
Lindane 0.38 nd nd
Pentachloronitrobenzene
1.68 nd nd
BHC delta isomer
0.88 nd nd
Pentachloroaniline
1.35 nd nd
Pentachlorothioanisole
0.15 nd nd
Total 5.83 0.00 0.00
______________________________________
All Units are expressed in μg/mL.
Claims (22)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/176,348 US6132726A (en) | 1998-10-21 | 1998-10-21 | Process for removing impurities from natural product extracts |
| PCT/US1999/024515 WO2000023090A1 (en) | 1998-10-21 | 1999-10-20 | Process for removing impurities from natural product extracts |
| EP99956616A EP1123107A1 (en) | 1998-10-21 | 1999-10-20 | Process for removing impurities from natural product extracts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/176,348 US6132726A (en) | 1998-10-21 | 1998-10-21 | Process for removing impurities from natural product extracts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US6132726A true US6132726A (en) | 2000-10-17 |
Family
ID=22643987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/176,348 Expired - Fee Related US6132726A (en) | 1998-10-21 | 1998-10-21 | Process for removing impurities from natural product extracts |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6132726A (en) |
| EP (1) | EP1123107A1 (en) |
| WO (1) | WO2000023090A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555074B1 (en) * | 2000-04-05 | 2003-04-29 | Earle C. Sweet | Apparatus for making herbal extracts using percolation |
| US20060286134A1 (en) * | 2005-06-21 | 2006-12-21 | The Coca-Cola Company | Method for Removing Contaminants from Essential Oils |
| US20070065526A1 (en) * | 2005-09-19 | 2007-03-22 | Gow Robert T | Methods and compositions comprising Panax species |
| CN102888281A (en) * | 2012-10-19 | 2013-01-23 | 吉林人参研究院 | Method for extracting ginseng volatile oil by supercritical CO2 |
| CN112007417A (en) * | 2020-08-20 | 2020-12-01 | 赣州禾绿康健生物技术有限公司 | Device and method for removing carbendazim in ganoderma triterpene extract |
| CN113546098A (en) * | 2020-04-24 | 2021-10-26 | 泰州医药城国科化物生物医药科技有限公司 | Method for removing pesticide residues of pentachloronitrobenzene and pentachloroaniline in ginseng extract |
| JP2022526687A (en) * | 2019-03-21 | 2022-05-25 | 和偉 李 | Lyophilized preparation and its preparation method and application |
| US20240032490A1 (en) * | 2022-07-29 | 2024-02-01 | Rain Bird Corporation | Irrigation systems and methods with satellite communications |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20090548A1 (en) * | 2009-04-06 | 2010-10-07 | Indena Spa | PROCESS OF REMOVAL OF PESTICIDES FROM GINKGO BILOBA EXTRACTS AND EXTRACTS OBTAINED FROM SUCH PROCESS |
| CN110420642A (en) * | 2019-07-31 | 2019-11-08 | 湘潭大学 | TiO2The preparation method of the activated carbon supported nickel-base catalyst of modification and its application in chloronitrobenzene hydrogenation reaction |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3901875A (en) * | 1972-03-31 | 1975-08-26 | Pacific Chem Ind Co | Extraction of ginseng saponin |
| US3950266A (en) * | 1973-11-28 | 1976-04-13 | Rutgers Research And Educational Foundation | Method of producing an antioxidant composition from rosemary and sage |
| US4317816A (en) * | 1979-08-13 | 1982-03-02 | Osaka Chemical Laboratory Co., Ltd. | Saponin containing composition effective against adrenal atrophy |
| US4361697A (en) * | 1981-05-21 | 1982-11-30 | F. K. Suzuki International, Inc. | Extraction, separation and recovery of diterpene glycosides from Stevia rebaudiana plants |
| US4610790A (en) * | 1984-02-10 | 1986-09-09 | Sterimatics Company Limited Partnership | Process and system for producing sterile water and sterile aqueous solutions |
| US4621137A (en) * | 1982-12-24 | 1986-11-04 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Alpha-glycosyl ginsenosides |
| US4755504A (en) * | 1985-10-03 | 1988-07-05 | Yaguang Liu | Pharmaceutical composition from Tienchi |
| US4842878A (en) * | 1986-09-24 | 1989-06-27 | Hopfen-Extraktion Hvg Bart, Raiser & Co. | Process for the extraction of nonpolar constituents of hops |
| US5093123A (en) * | 1989-02-04 | 1992-03-03 | Skw Trostberg Aktiengesellschaft | Process for the removal of pesticides from ginseng roots |
| US5137878A (en) * | 1989-01-13 | 1992-08-11 | Pang Peter K T | Composition and method for treatment of senile dementia |
| US5368411A (en) * | 1992-08-20 | 1994-11-29 | Tuboscope Vetco International, Inc. | Method and apparatus for on the site cleaning of contaminated soil |
| US5484538A (en) * | 1993-09-14 | 1996-01-16 | Texavia International, Inc. | Multiple service water purifier and dispenser and process of purifying water |
| US5585505A (en) * | 1991-07-18 | 1996-12-17 | B.V. Chemische Pharmaceutische Industrie "Luxan" | Hatching agent for the potato cyst nematode |
| US5660832A (en) * | 1994-07-14 | 1997-08-26 | Emil Flachsmann Ag | Process for the preparation of pesticide-poor concentrates of active components of plants |
| US5843911A (en) * | 1995-02-10 | 1998-12-01 | Suntory Limited | Hyaluronidase inhibitor containing god-type ellagitannin as active ingredient |
-
1998
- 1998-10-21 US US09/176,348 patent/US6132726A/en not_active Expired - Fee Related
-
1999
- 1999-10-20 EP EP99956616A patent/EP1123107A1/en not_active Withdrawn
- 1999-10-20 WO PCT/US1999/024515 patent/WO2000023090A1/en not_active Ceased
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3901875A (en) * | 1972-03-31 | 1975-08-26 | Pacific Chem Ind Co | Extraction of ginseng saponin |
| US3950266A (en) * | 1973-11-28 | 1976-04-13 | Rutgers Research And Educational Foundation | Method of producing an antioxidant composition from rosemary and sage |
| US4317816A (en) * | 1979-08-13 | 1982-03-02 | Osaka Chemical Laboratory Co., Ltd. | Saponin containing composition effective against adrenal atrophy |
| US4361697A (en) * | 1981-05-21 | 1982-11-30 | F. K. Suzuki International, Inc. | Extraction, separation and recovery of diterpene glycosides from Stevia rebaudiana plants |
| US4621137A (en) * | 1982-12-24 | 1986-11-04 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Alpha-glycosyl ginsenosides |
| US4610790A (en) * | 1984-02-10 | 1986-09-09 | Sterimatics Company Limited Partnership | Process and system for producing sterile water and sterile aqueous solutions |
| US4755504A (en) * | 1985-10-03 | 1988-07-05 | Yaguang Liu | Pharmaceutical composition from Tienchi |
| US4946695A (en) * | 1986-09-24 | 1990-08-07 | Hopfen-Extraktion Hvg Bart, Raiser & Co. | Process for the extraction of nonpolar constituents from plant material |
| US4842878A (en) * | 1986-09-24 | 1989-06-27 | Hopfen-Extraktion Hvg Bart, Raiser & Co. | Process for the extraction of nonpolar constituents of hops |
| US5137878A (en) * | 1989-01-13 | 1992-08-11 | Pang Peter K T | Composition and method for treatment of senile dementia |
| US5093123A (en) * | 1989-02-04 | 1992-03-03 | Skw Trostberg Aktiengesellschaft | Process for the removal of pesticides from ginseng roots |
| US5585505A (en) * | 1991-07-18 | 1996-12-17 | B.V. Chemische Pharmaceutische Industrie "Luxan" | Hatching agent for the potato cyst nematode |
| US5368411A (en) * | 1992-08-20 | 1994-11-29 | Tuboscope Vetco International, Inc. | Method and apparatus for on the site cleaning of contaminated soil |
| US5484538A (en) * | 1993-09-14 | 1996-01-16 | Texavia International, Inc. | Multiple service water purifier and dispenser and process of purifying water |
| US5660832A (en) * | 1994-07-14 | 1997-08-26 | Emil Flachsmann Ag | Process for the preparation of pesticide-poor concentrates of active components of plants |
| US5843911A (en) * | 1995-02-10 | 1998-12-01 | Suntory Limited | Hyaluronidase inhibitor containing god-type ellagitannin as active ingredient |
Non-Patent Citations (4)
| Title |
|---|
| Fischer Scientific Catalog, pp. 1192 1197, 1988. * |
| Fischer Scientific Catalog, pp. 1192-1197, 1988. |
| VWR Scientific Catalog, pp. 652 653 and 655, 1989/90. * |
| VWR Scientific Catalog, pp. 652-653 and 655, 1989/90. |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555074B1 (en) * | 2000-04-05 | 2003-04-29 | Earle C. Sweet | Apparatus for making herbal extracts using percolation |
| US20030124204A1 (en) * | 2000-04-05 | 2003-07-03 | Sweet Earle C. | Method for Making Herbal Extracts Using Percolation |
| US7033619B2 (en) | 2000-04-05 | 2006-04-25 | Sweet Earle C | Method for making herbal extracts using percolation |
| US20060286134A1 (en) * | 2005-06-21 | 2006-12-21 | The Coca-Cola Company | Method for Removing Contaminants from Essential Oils |
| US7595070B2 (en) | 2005-06-21 | 2009-09-29 | The Coca-Cola Company | Method for removing contaminants from essential oils |
| US20070065526A1 (en) * | 2005-09-19 | 2007-03-22 | Gow Robert T | Methods and compositions comprising Panax species |
| CN102888281A (en) * | 2012-10-19 | 2013-01-23 | 吉林人参研究院 | Method for extracting ginseng volatile oil by supercritical CO2 |
| JP2022526687A (en) * | 2019-03-21 | 2022-05-25 | 和偉 李 | Lyophilized preparation and its preparation method and application |
| CN113546098A (en) * | 2020-04-24 | 2021-10-26 | 泰州医药城国科化物生物医药科技有限公司 | Method for removing pesticide residues of pentachloronitrobenzene and pentachloroaniline in ginseng extract |
| CN112007417A (en) * | 2020-08-20 | 2020-12-01 | 赣州禾绿康健生物技术有限公司 | Device and method for removing carbendazim in ganoderma triterpene extract |
| US20240032490A1 (en) * | 2022-07-29 | 2024-02-01 | Rain Bird Corporation | Irrigation systems and methods with satellite communications |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1123107A1 (en) | 2001-08-16 |
| WO2000023090A1 (en) | 2000-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1536810B1 (en) | Extraction of pharmaceutically active cannabinoids from plant materials | |
| Skrzypczak-Pietraszek et al. | Chemical profile and seasonal variation of phenolic acid content in bastard balm (Melittis melissophyllum L., Lamiaceae) | |
| US4946695A (en) | Process for the extraction of nonpolar constituents from plant material | |
| CZ290247B6 (en) | Process for preparing pesticide-poor concentrates of active substances from plants | |
| US6132726A (en) | Process for removing impurities from natural product extracts | |
| Seabra et al. | Two-step high pressure solvent extraction of walnut (Juglans regia L.) husks: scCO2+ CO2/ethanol/H2O | |
| Kumar | Herbal bioactives and food fortification: extraction and formulation | |
| Oleszek et al. | Alfalfa saponins—the allelopathic agents | |
| Harvey Jr et al. | Metabolism of oxamyl in plants | |
| CN100439362C (en) | The Extraction and Separation Method of Neochamaerina B in Daphne chamaejasmin and Its Application | |
| CN113087751A (en) | Flavone with lipase inhibitory activity and preparation method and application thereof | |
| US6942882B2 (en) | Hepatic disorder suppressant | |
| CN100519562C (en) | Process for isolation of imperatorin from aegle marmelos correa | |
| WO2025043944A1 (en) | Use of ester compound and related extract as biostimulant | |
| JP2579255B2 (en) | Angiotensin converting enzyme activity inhibitor from Tochu leaf extract | |
| US6589573B2 (en) | Xanthine oxidase inhibitor and method for producing the same | |
| CN1283634C (en) | Felt wort extract, its preparation method and use | |
| KR20010084325A (en) | Method for preparing alkaloid using supercritical fluid from plant | |
| Zabar et al. | Phytochemical Diversity in Seven Grapevine Varieties Using GC-MASS | |
| JP3015363B1 (en) | Method for producing antioxidant food material from wakame bud strain | |
| Yusupova et al. | Technologies for producing drugs and biologically active additives based on ecdysteroids from plants Rhaponticum Carthamoides, Silene Praemixta, and Ajuga Turkestanica | |
| LeFevre | CONCENTRATION OF A GROWTH INHIBITOR FROM AGROPYRON REPENS,(QUACKGRASS). | |
| JP4673474B2 (en) | New liver disorder inhibitor | |
| ABD et al. | Phytochemical Diversity in Seven Grapevine Varieties Using GC-MS. | |
| JPS6311000B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: HAUSER, INC., COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAUGHENBAUGH, RANDALL J.;BAILEY, DAVID T.;GAMBLE, WILLIAM R.;AND OTHERS;REEL/FRAME:009533/0361 Effective date: 19981021 |
|
| AS | Assignment |
Owner name: WELLS FARGO BANK, NATIONAL ASSOCIATION, CALIFORNIA Free format text: SECURITY AGREEMENT;ASSIGNOR:HAUSER, INC.;REEL/FRAME:010078/0380 Effective date: 19990611 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20041017 |